

## State of Louisiana

Louisiana Department of Health Office of Public Health

## **CONFIDENTIAL REPORTING WORKSHEET**

Pt. Name:			MRN:			_SS#					
Address:						Те	: (	)			
City:	Parish:				State:	Zip	:				
Sex (at birth):	Date of Birth:			Country of Birth: USA			Date of	of death:	Sta	ate of death:	
🖵 Male 🖵 Female	<u> </u>			Othe	er:		/_	/			
Gender (as applicable):           Male to female transgender           Female to male transgender	Race (check all th American India Black/African A	an/Alaskan 🛛 American 🗍		e Ha n	waiian 🔲 White 🔲 Unknowi	<u>n</u>	Hispa D Y	nic Ethni N	l Un		
Diagnostic Tests	Collection Date (mm/dd/yyyy)	Ordering Site (if other than reporting facility)	T diferit filotory / filok f				Factors (please complete all lines)				
Preliminary (report positives):          IA 1       IA 1/2       Check if rapid         Ag/Ab Combo (4th Gen, lab-based)         Determine (rapid) Ag+Ab+         Supplemental/Differentiating (report all):         Western Blot       PosNeg         Multispot       1+2+Neg         Geenius       1+2+Neg         Viral detection - Qual DNA or RNA         PCR (NAT):       Pos/DetcNeg         Other (specify):         If labs not available, date reporting	/ / / / Check if result Indeterminate / / / /				<ul> <li>Sex with male</li> <li>Sex with fema</li> <li>Injected nonp</li> <li>Heterosexua</li> <li>Injecting Dr</li> <li>Bisexual Ma</li> <li>Person with</li> <li>Transfusion</li> <li>Person with</li> <li>Rec'd clotting f</li> <li>Rec'd transfusi</li> <li>Dates (mo/yr</li> <li>Rec'd tissue/or</li> </ul>	ale presci ll rela ug Us ale (fo hem /trans know actor on of ): Ear	(for female pts) mophilia/coagulation disorder insplant recipient own HIV infection or for hemophilia/coag. disorder of other blood/blood components arliestLatest n transplant or artificial insemination				
facility documented pt's diagnosis: Clinical Status Tests					Blood/body flui setting (mo/yr)						
Viral load – Quantitative RNA Copies/ml :	/ /				Date of first diagn State of last reside						
CD4 T-lymphocytes:	/ /		Treatment History Has patient ever taken antiretroviral medications (ARVs)?								
Opportunistic Infections (OIs) – see list on reverse. Please document typ and date of diagnosis in Comments section.         Most recent negative test:       /         per lab report       per patient				Date ARVs last used://							
Insurance provider:				ARV medications:							
Partner Services:I give(see reverse for info)I will	rn infant?	fes No fis/her HIV t lealth staff permotification for this	Unk Unk test re hission s patie	If y If y sults to co ent.	ves, estimated date c ves, date of most rec City/Sta	ent de ate: _ D es foi	elivery:	/	/		
Reporting Facility:						- 1		fax or call			
Address:	City:State:Zip:						Tarsia William Field Epi Regions 1 &3 Ph:504 599- 0496 (o) 504 877-4329 (cell) Fax: (504) 568- 2453				
Reporting Physician:	Phone:										
Person Completing Form:	Phone:										

## **To Our Providers:**

This worksheet was developed to assist with timely reporting of HIV cases by the diagnosing and/or managing physician, by collecting the most critical information requested on the Centers for Disease Control and Prevention (CDC)'s Adult Case Report Form. In some cases, staff of the STD/HIV Program (SHP), under the Dept of Health and Hospitals Office of Public Health, may need to contact the provider for additional information not included on this worksheet. If a provider prefers to complete the CDC Adult Case Report Form him- or herself, copies may be obtained from the SHP contact listed at the bottom of the form. Case reports may also be made by phone to the SHP contact, or SHP staff can complete the required forms on site via a chart review. *Please include as much information as is available; partial or approximate dates are acceptable for historical information*.

**Reporting Requirements:** Louisiana's Public Health Sanitary Code (Title 51, Part II, Chapter 1) requires that any physician practicing medicine in the State of Louisiana who attends, examines, or prescribes to a person with HIV infection must report the case by the end of the work week after the existence of a case, suspected case, or a positive laboratory result is known (Class C). HIV infection in pregnancy and perinatal HIV exposure are reportable within one business day (Class B). Other health care providers, laboratories, and other entities have similar reporting requirements.

**HIPAA Guidelines Related to Disclosures for Public Health Activities**: The Privacy Rule permits covered entities to disclose protected health information, without authorization, to public health authorities who are legally authorized to receive such reports for the purpose of preventing or controlling disease, injury, or disability. See 45 CFR 164.512(b)(1)(i).

**Risk Factors and Cases of Public Health Importance:** Information on patient risk factors and likely mode of HIV transmission is used in planning prevention activities and to more effectively allocate HIV-related resources. The CDC also closely monitors for any new cases of **HIV-2**; for HIV transmission through a rare or unusual route such as transfusion, transplant, or occupational exposure; and for any cases in children age 12 and under not due to perinatal HIV exposure. Such cases, collectively known as "Cases of Public Health Importance (COPHI)", often require a special investigation and should be reported to your regional contact as soon as suspected.

**Partner Services:** OPH Disease Intervention Specialists (DIS) make a good faith effort to locate any individual identified as a spouse, sexual contact, or needle-sharing partner of a person newly diagnosed with HIV infection (source patient), to notify the partner(s) of the possible exposure, provide counseling about the risk of infection, and offer testing for HIV infection and other STDs. In performing these activities, the DIS first attempt to contact the source patient's medical provider to determine how partner notification will be conducted. If neither the source patient nor the medical provider is able to adequately conduct this notification, the DIS will seek to interview the source patient directly to identify partners for counseling, testing, and referral. *Notification of partners is conducted in such a manner as to maintain the confidentiality of the source patient.* Partner Services is a valuable prevention activity, as well as a means to offer follow-up services and support to newly diagnosed patients and promote their linkage to care.

(Continued from Clinical Status section on front)

**Opportunistic Infections (OIs):** If patient has a current or previous diagnosis of any of the following, please note the condition and date of diagnosis in Comments.

- Candidiasis, bronchi, trachea, or lungs
- Candidiasis, esophageal
- Carcinoma, invasive cervical
- Coccidiodomycosis, disseminated or extrapulmonary
- Cryptococcosis, extrapulmonary
- Cryptosporidiosis, chronic intestinal (>1 mo. duration)
- Cytomegalovirus disease (other than in liver, spleen, or lymph nodes)
- Cytomegalovirus retinitis (with loss of vision)
- HIV encephalopathy
- Herpes simplex: chronic ulcer(s) (>1 mo. duration); or bronchitis, pneumonitis, or esophagitis
- Histoplasmosis, disseminated or extrapulmonary
- Isosporiasis, chronic intestinal (>1 mo. duration)
- Kaposi's sarcoma

- Lymphoma, Burkitt's (or equivalent term)
- Lymphoma, immunoblastic (or equivalent term)
- Lymphoma, primary in brain
- Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary
- M.tuberculosis, pulmonary
- M.tuberculosis, disseminated or extrapulmonary
- *Mycobacterium*, of other species or unidentified species, disseminated or extrapulmonary
- Pneumocystis jerovecii pneumonia (formerly P. carinii)
- Pneumonia, recurrent, within a 12-month period
- Progressive multifocal leukoencephalopathy
- Salmonella septicemia, recurrent
- Toxoplasmosis of brain
- Wasting syndrome due to HIV

Comments (Opportunistic infections, additional risk information, antiretroviral meds, partner information, etc.):